DYADIC INTERNATIONAL

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

07 فبراير 2022 07:30:01 بحسب Nasdaq GlobeNewswire

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

20 يناير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

22 ديسمبر 2021 08:12:47 بحسب Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

17 ديسمبر 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

10 نوفمبر 2021 15:00:00 بحسب Nasdaq GlobeNewswire

Dyadic Appoints Chief Business Officer to Executive Leadership Team

09 نوفمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

27 أكتوبر 2021 15:30:00 بحسب Nasdaq GlobeNewswire

Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

10 سبتمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

11 أغسطس 2021 07:35:40 بحسب Nasdaq GlobeNewswire

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

27 يوليو 2021 07:20:00 بحسب Nasdaq GlobeNewswire

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

28 يونيو 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic announces development of COVID-19 Vaccine in India

26 مايو 2021 07:30:01 بحسب Nasdaq GlobeNewswire

Dyadic to Present at Upcoming Events

03 مايو 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”

22 أبريل 2021 07:30:01 بحسب Nasdaq GlobeNewswire

UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial

29 مارس 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

23 مارس 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

22 مارس 2021 20:00:00 بحسب Nasdaq GlobeNewswire

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

22 مارس 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

18 مارس 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting

09 مارس 2021 07:30:00 بحسب Nasdaq GlobeNewswire